Archives of Neuroscience

Published by: Kowsar

Discovery of the Endocannabinoid System: A Breakthrough in Neuroscience

Parichehr Hassanzadeh 1 , *
Author Information
1 Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Neuroscience: October 01, 2014, 1 (3); e15030
  • Published Online: October 1, 2014
  • Article Type: Review Article
  • Received: September 24, 2013
  • Revised: December 3, 2013
  • Accepted: December 29, 2013
  • DOI: 10.5812/archneurosci.15030

To Cite: Hassanzadeh P. Discovery of the Endocannabinoid System: A Breakthrough in Neuroscience, Arch Neurosci. 2014 ; 1(3):e15030. doi: 10.5812/archneurosci.15030.

Abstract
Copyright © 2014, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisitions
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 1998; 21(12): 521-8[PubMed]
  • 2. Fernandez-Ruiz J, Berrendero F, Hernandez ML, Ramos JA. The endogenous cannabinoid system and brain development. Trends Neurosci. 2000; 23(1): 14-20[PubMed]
  • 3. Wilson RI, Kunos G, Nicoll RA. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron. 2001; 31(3): 453-62[PubMed]
  • 4. Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, et al. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci U S A. 2000; 97(10): 5044-9[PubMed]
  • 5. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. 2003; 111(1): 43-50[DOI][PubMed]
  • 6. Centonze D, Rossi S, Finazzi-Agro A, Bernardi G, Maccarrone M. The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis. Int Rev Neurobiol. 2007; 82: 171-86[DOI][PubMed]
  • 7. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997; 74(2): 129-80[PubMed]
  • 8. van der Stelt M, Di Marzo V. Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med. 2005; 7(1-2): 37-50[DOI][PubMed]
  • 9. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998; 95(14): 8268-73[PubMed]
  • 10. Molina-Holgado F, Molina-Holgado E, Guaza C, Rothwell NJ. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J Neurosci Res. 2002; 67(6): 829-36[PubMed]
  • 11. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A. 1992; 89(9): 3825-9[PubMed]
  • 12. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, Lutz B. Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci. 2004; 19(7): 1691-8[DOI][PubMed]
  • 13. Barna I, Zelena D, Arszovszki AC, Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci. 2004; 75(24): 2959-70[DOI][PubMed]
  • 14. Hassanzadeh P, Hassanzadeh A. The Role of the Endocannabinoids in Suppression of the Hypothalamic-pituitary-adrenal Axis Activity by Doxepin. Iran J Basic Med Sci. 2011; 14(5): 414-21[PubMed]
  • 15. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A. 2005; 102(51): 18620-5[DOI][PubMed]
  • 16. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med. 2001; 7(5): 541-7[DOI][PubMed]
  • 17. Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR, et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport. 1997; 8(2): 491-6[PubMed]
  • 18. Jenny M, Schrocksnadel S, Uberall F, Fuchs D. The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism. Pharmaceuticals. 2010; 3(8): 2647-60[PubMed]
  • 19. Hassanzadeh P, Rahimpour S. The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs. Psychopharmacology (Berl). 2011; 215(1): 129-41[DOI][PubMed]
  • 20. Hassanzadeh P, Hassanzadeh A. Involvement of the neurotrophin and cannabinoid systems in the mechanisms of action of neurokinin receptor antagonists. Eur Neuropsychopharmacol. 2011; 21(12): 905-17[DOI][PubMed]
  • 21. Hassanzadeh P, Hassanzadeh A. The CB(1) receptor-mediated endocannabinoid signaling and NGF: the novel targets of curcumin. Neurochem Res. 2012; 37(5): 1112-20[DOI][PubMed]
  • 22. Hassanzadeh P, Hassanzadeh A. Implication of NGF and endocannabinoid signaling in the mechanism of action of sesamol: a multi-target natural compound with therapeutic potential. Psychopharmacology (Berl). 2013; 229(4): 571-8[DOI][PubMed]
  • 23. Hassanzadeh P, Arbabi E. Cannabinoid CB1 Receptors Mediate the Gastroprotective Effect of Neurotensin. Iran J Basic Med Sci. 2012; 15(3): 803-10[PubMed]
  • 24. Hassanzadeh P, Rostami F. Cannabinoid CB1 receptors are involved in neuroleptic-induced enhancement of brain neurotensin. Iran J Basic Med Sci. 2013;
  • 25. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 2000; 14(10): 1432-8[PubMed]
  • 26. Brotchie JM. CB1 cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol. 2003; 3(1): 54-61[PubMed]
  • 27. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci. 2002; 22(16): 6900-7[PubMed]
  • 28. Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, et al. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci. 2009; 29(11): 2177-86[DOI][PubMed]
  • 29. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience. 2000; 97(3): 505-19[PubMed]
  • 30. Lastres-Becker I, Fezza F, Cebeira M, Bisogno T, Ramos JA, Milone A, et al. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport. 2001; 12(10): 2125-9[PubMed]
  • 31. Lastres-Becker I, De Miguel R, Fernandez-Ruiz JJ. The endocannabinoid system and Huntington's disease. Curr Drug Targets CNS Neurol Disord. 2003; 2(5): 335-47[PubMed]
  • 32. Huntley A. A review of the evidence for efficacy of complementary and alternative medicines in MS. Int MS J. 2006; 13(1): 5-40[PubMed]
  • 33. Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci. 2003; 23(7): 2511-6[PubMed]
  • 34. Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, Molina-Holgado F, Borrell J, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci. 2002; 22(22): 9742-53[PubMed]
  • 35. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003; 362(9395): 1517-26[DOI][PubMed]
  • 36. Cadotte DW, Fehlings MG. Spinal cord injury: a systematic review of current treatment options. Clin Orthop Relat Res. 2011; 469(3): 732-41[DOI][PubMed]
  • 37. Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, Docagne F, Hagen C, Bisogno T, et al. The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis. 2009; 33(1): 57-71[DOI][PubMed]
  • 38. Arevalo-Martin A, Garcia-Ovejero D, Sierra-Palomares Y, Paniagua-Torija B, Gonzalez-Gil I, Ortega-Gutierrez S, et al. Early endogenous activation of CB1 and CB2 receptors after spinal cord injury is a protective response involved in spontaneous recovery. PLoS One. 2012; 7(11)[DOI][PubMed]
  • 39. McCormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol. 2001; 63: 815-46[DOI][PubMed]
  • 40. Wallace MJ, Martin BR, DeLorenzo RJ. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol. 2002; 452(3): 295-301[PubMed]
  • 41. Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol. 2001; 428(1): 51-7[PubMed]
  • 42. Ben-Ari Y, Cossart R. Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci. 2000; 23(11): 580-7[PubMed]
  • 43. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003; 302(5642): 84-8[DOI][PubMed]
  • 44. Klijn CJ, Hankey GJ, American Stroke A, European Stroke I. Management of acute ischaemic stroke: new guidelines from the American Stroke Association and European Stroke Initiative. Lancet Neurol. 2003; 2(11): 698-701[PubMed]
  • 45. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004; 89(1): 134-41[DOI][PubMed]
  • 46. Hayakawa K, Mishima K, Irie K, Hazekawa M, Mishima S, Fujioka M, et al. Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology. 2008; 55(8): 1280-6[DOI][PubMed]
  • 47. Lavie G, Teichner A, Shohami E, Ovadia H, Leker RR. Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia. Brain Res. 2001; 901(1-2): 195-201[PubMed]
  • 48. Weksler ME, Gouras G, Relkin NR, Szabo P. The immune system, amyloid-beta peptide, and Alzheimer's disease. Immunol Rev. 2005; 205: 244-56[DOI][PubMed]
  • 49. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005; 25(8): 1904-13[DOI][PubMed]
  • 50. van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D, et al. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci. 2006; 63(12): 1410-24[DOI][PubMed]
  • 51. Molina-Holgado F, Pinteaux E, Heenan L, Moore JD, Rothwell NJ, Gibson RM. Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol Cell Neurosci. 2005; 28(1): 189-94[DOI][PubMed]
  • 52. Hohmann AG, Tsou K, Walker JM. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J Neurophysiol. 1999; 81(2): 575-83[PubMed]
  • 53. Guhring H, Hamza M, Sergejeva M, Ates M, Kotalla CE, Ledent C, et al. A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol. 2002; 454(2-3): 153-63[PubMed]
  • 54. Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. 1999; 848(1-2): 183-90[PubMed]
  • 55. Murillo-Rodriguez E, Cabeza R, Mendez-Diaz M, Navarro L, Prospero-Garcia O. Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor. Neuroreport. 2001; 12(10): 2131-6[PubMed]
  • 56. Murillo-Rodriguez E, Blanco-Centurion C, Sanchez C, Piomelli D, Shiromani PJ. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep. 2003; 26(8): 943-7[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments